GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » Retained Earnings

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Retained Earnings : $-58.62 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Clarity Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2023 was $-58.62 Mil.

Clarity Pharmaceuticals's quarterly retained earnings declined from Dec. 2022 ($-38.45 Mil) to Jun. 2023 ($-47.23 Mil) and declined from Jun. 2023 ($-47.23 Mil) to Dec. 2023 ($-58.62 Mil).

Clarity Pharmaceuticals's annual retained earnings increased from . 20 ($0.00 Mil) to Jun. 2022 ($-32.18 Mil) but then declined from Jun. 2022 ($-32.18 Mil) to Jun. 2023 ($-47.23 Mil).


Clarity Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Clarity Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Retained Earnings Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
Retained Earnings
-32.18 -47.23

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Retained Earnings Get a 7-Day Free Trial -30.45 -32.18 -38.45 -47.23 -58.62

Clarity Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Clarity Pharmaceuticals  (OTCPK:CLRPF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.